Mutation analysis of the WNT-4 gene in patients with polycystic ovary syndrome

References

• Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
   PubMed Web of Science ®Google Scholar
• Asunción M, Calvo R M, San Millán J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434–2438
   Google Scholar
• Carmina E, Rosato F, Janni A, Rizzo M, Longo R A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2–6
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H F, Luque-Ramírez M, San Millán J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26: 251–282
   PubMed Web of Science ®Google Scholar
• Ehrmann D A, Barnes R B, Rosenfield R L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16: 322–353
   PubMed Web of Science ®Google Scholar
• Nelson V L, Legro R S, Strauss J F, 3rd, McAllister J M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13: 946–957
   PubMed Web of Science ®Google Scholar
• Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001; 52: 401–419
   PubMed Web of Science ®Google Scholar
• Dale T C. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329: 209–223
   PubMed Web of Science ®Google Scholar
• Biason-Lauber A, Konrad D, Navratil F, Schoenle E J. A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004; 351: 792–798
   PubMed Web of Science ®Google Scholar
• Vainio S, Heikkilä M, Kispert A, Chin N, McMahon A P. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397: 405–409
   PubMed Web of Science ®Google Scholar
• Jeays-Ward K, Hoyle Ch, Brennan J, Dandonneau M, Alldus G, Capel B, Swain A. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 2003; 130: 3663–3670
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey J. Clinical assessment on body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1445
   PubMed Web of Science ®Google Scholar
• Söderlund D, Canto P, Carranza-Lira S, Méndez J P. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod 2005; 20: 965–969
   PubMed Web of Science ®Google Scholar
• Sambrook J, Russell D. Preparation and analysis of eukaryotic genomic DNA. Molecular cloning: A laboratory manual. 3rd ed, C Nolan. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2001; 6.1–6.31
   Google Scholar
• Canto P, Razo E, Söderlund D, Calzada-León R, Ruíz-Reyes M L, Ramón G, Braun-Roth G, Méndez J P. Screening for mutations in the WNT-4 gene in patients with 46,XX true hermaphroditism. Mol Genet Metab 2004; 83: 341–343
   Google Scholar
• Carmina E, Lobo R A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899
   PubMed Web of Science ®Google Scholar
• Carey A H, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873–1876
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Gharani N, Waterworth D M, Batty S, White D, Gilling-Smith C, Conway G S, McCarthy M, Franks S, Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997; 6: 397–402
   PubMed Web of Science ®Google Scholar
• Ciaraldi T P, el-Roeiy A, Madar Z, Reichart D, Olefsky J M, Yen S S. Cellular mechanism of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577–583
   PubMed Web of Science ®Google Scholar
• Kiddy D S, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed M J, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105–111
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book C B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801–810
   PubMed Web of Science ®Google Scholar
• Legro R S. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am 1999; 28: 379–396
   PubMed Web of Science ®Google Scholar
• Treier M, Gleiberman A S, O'Connell S M, Szeto D P, McMahon J A, McMahon A P, Rosenfeld M G. Multistep signaling requirements for pituitary. Genes Dev 1998; 12: 1691–1704
   PubMed Web of Science ®Google Scholar
• Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey S K, McMahon J A, McMahon A P, Weinberg R A. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 2000; 14: 650–654
   PubMed Web of Science ®Google Scholar
• Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 2002; 143: 4358–4365
   PubMed Web of Science ®Google Scholar
• Stark K, Vainio S, Vassileva G, McMahon A P. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994; 372: 679–683
   PubMed Web of Science ®Google Scholar
• Jordan B K, Mohammed M, Ching S T, Délot E, Chen X N, Dewing P, Swain A, Nagesh Rao P, Elejalde B R, Vilain E. Up-regulation of Wnt-4 signalling and dosage-sensitive sex reversal in humans. Am J Hum Genet 2001; 68: 1102–1109
   Google Scholar
• Hsieh M, Johnson M A, Greenberg N M, Richards J S. Regulated expression of Wnts and Frizzleds at specific stages of follicular development in the rodent ovary. Endocrinology 2002; 143: 898–908
   Google Scholar
• Jeays-Ward K, Dandonneau M, Swain A. Wnt4 is required for proper male as well as female sexual development. Dev Biol 2004; 276: 431–440
   PubMedGoogle Scholar
• Heikkilä M, Prunskaite R, Naillat F, Itaranta P, Vuoristo J, Leppaluoto J, Peltoketo H, Vainio S. The partial female to male sex reversal in Wnt-4 deficient females involves induced expression of testosterone biosynthetic genes and testosterone production, and depends on androgen action. Endocrinology 2005; 146: 4016–4023
   PubMed Web of Science ®Google Scholar